{"id":"NCT04842643","sponsor":"Takeda","briefTitle":"An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease","officialTitle":"A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-04-27","primaryCompletion":"2024-04-25","completion":"2024-04-25","firstPosted":"2021-04-13","resultsPosted":"2025-01-20","lastUpdate":"2025-01-20"},"enrollment":12,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immunodeficiency Disease"],"interventions":[{"type":"BIOLOGICAL","name":"IGSC 20% infusion","otherNames":["Immune Globulin Infusion (Human)"]}],"arms":[{"label":"IGSC, 20%","type":"EXPERIMENTAL"}],"summary":"This study is an extension study for participants with primary immunodeficiency disorders who were previously treated with IGSC, 20% in the TAK-664-3001 study. They must have completed that study or be about to complete it before joining this study. Participants will continue treatment with IGCS, 20% in this study.\n\nThe main aim of this study is to check for side effects from long-term treatment with IGSC, 20% . This medicine is not yet licensed in Japan, so participants will be treated with IGSC, 20% until it becomes commercially available.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Non-serious TEAEs","timeFrame":"From the first dose of the study drug in the current extension study TAK-664-3002, up to 3 years post-dose","effectByArm":[{"arm":"IGSC, 20%","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":8,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/60769026688ad8001f42fb97"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":12},"commonTop":["Headache","COVID-19","Pyrexia","Vaccination complication","Injection site swelling"]}}